| Literature DB >> 21726878 |
Libin Li1, Makiko Matsumoto, Timothy J Seabrook, Celine Cojean, Volker Brinkman, Andrew R Pachner.
Abstract
FTY720 (fingolimod) has demonstrated efficacy in multiple sclerosis (MS). We evaluated the effects of FTY720 on progressive disability, viral load, and antibody responses in mice infected with Theiler's murine encephalomyocarditis virus (TMEV). FTY720 and phosphorylated FTY720 (FTY720-P) were detected in the brain after intraperitoneal injection of the drug. Bioactivity of FTY720 was confirmed by reduced numbers of mononuclear cells in the spleen and blood after treatment. No significant differences were found in disability progression, viral load, and serum antibody responses between the FTY720-treated versus the PBS-treated mice. There was less production of IgG within the CNS in the FTY-treated group on some measures.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21726878 DOI： 10.1016/j.jns.2011.06.029
Source DB: PubMed Journal: J Neurol Sci ISSN： 0022-510X Impact factor: 3.181